You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Latest FDA Articles
Popular FDA Articles
Highly Recommended FDA Articles
Send a link to this page to your friends and colleagues.
The Food and Drug Adminsitration, reversing itself on a decision it made in October, has opened the way for a new treatment for diabetic macular edema to reach the U.S. market.
The treatment, Iluvien, is a tiny insert implanted into the eye via a needle. It carries a drug used to treat DME, a condition that develops in many people with diabetes and can lead to blindness.
Iluvien's developers, Watertown, MA-based pSivida and Alpharetta, GA-based Alimera Sciences, had been told only three months ago by the FDA that the federal agency could not approve the companies' application "in its present form."
Concerned with what it cited as "clinical and statistical deficiencies," as well as problems with Iluvien's manufacturing facility, the FDA said that addressing those concerns might require up to a year of additional product trials and meetings with agency advisors.
The new agency ruling removed those conditions, opening the way for the companies to prepare labeling proposals that they hope to submit to the FDA by late March. That step is a final step before the agency grants marketing approval.
Iluvien is approved for use in Europe, and potential sales of the device are expected to reach $400 million. Statistics for U.S. market revenues have not been estimated.
0 comments - Jan 1, 2014
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.